• AbbVie said subcutaneous induction dosing for Crohn’s drug Skyrizi is under regulatory review by the FDA and EMA.
• The company cited Phase 3 AFFIRM data showing week 24 endoscopic remission of 35.8% on Skyrizi vs 9.1% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610131515PR_NEWS_USPR_____CG70422) on October 13, 2026, and is solely responsible for the information contained therein.